Clinical trial · Observational
Survival Outcomes of Gynecologic Oncology Patients at Assiut University
Survival Outcomes of Gynecological Oncology Patients at Assiut University: A Retrospective Study (2022-2025)
NCT07232212CI-TRIAL-00097440not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynaecological Oncology | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 4 years
- description
- Overall survival (OS) is defined as the duration of time from the date of cancer diagnosis or initiation of treatment until death from any cause. Patients will be censored at the date of last follow-up if alive at study end. This outcome will provide a direct estimate of survival rates among gynecological oncology patients treated at Assiut University Hospital.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: \- Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal) Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025 All age groups included Exclusion Criteria: \- Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract Patients with incomplete medical records (e.g., missing pathology reports or treatment details) Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)
References
Publications (0)
Data not yet available
No reference posted for this study.